MarketCap
Facebook
X
Telegram
AbbVie Current Ratio | ABBV
Annual Current Ratio AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 3.18 | 0.983 | 1.28 | 1.65 | 1.5 | 1.41 | 2.59 | 2.27 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 | 0.983 | 1.86 |
Current Ratio of other stocks in the Biotechnology industry
| Issuer | Current Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brickell Biotech
BBI
|
6.18 | - | -5.38 % | $ 6.06 M |  USA |
 |
Applied Therapeutics
APLT
|
2.92 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
36.5 | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
1.59 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
0.393 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
5.81 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
4.77 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
4.21 | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
22nd Century Group
XXII
|
3.17 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
1.86 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
2.63 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
2.33 | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
0.679 | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
4.16 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
1.66 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
3.1 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
1.67 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
1.19 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
4.04 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
3.67 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
1.48 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
1.69 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
6.05 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
1.63 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
8.46 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
2.24 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
2.19 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
3.09 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
8.39 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
2.18 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
4.89 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.76 | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
4.19 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
1.6 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.05 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
1.77 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
1.52 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
0.939 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
11.4 | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
1.28 | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
1.24 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.53 | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
11.1 | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
1.38 | $ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
2.06 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
8.75 | - | - | - |  Russia |
 |
CorMedix
CRMD
|
1.96 | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
1.72 | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
6.6 | $ 50.09 | 3.15 % | $ 4.5 B | Schweiz |